Imatinib Accord

Imatinib, the active ingredient in Imatinib Accord, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting malignant cell proliferation.

GNH USA supplies Imatinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and pharmacy chains worldwide, with quality‑assured manufacturing and regulatory compliance across EU markets, and global reliable logistics support.

Imatinib is a tyrosine kinase inhibitor used in targeted cancer therapy.

- Chronic myeloid leukemia (CML): reduces disease burden by inhibiting BCR‑ABL driven cell proliferation. - Gastrointestinal stromal tumor (GIST): controls tumor growth by blocking KIT and PDGFRA signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides therapeutic benefit in adult patients by suppressing BCR‑ABL activity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools, often self‑limiting. - Muscle cramps: intermittent skeletal discomfort. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - Cardiotoxicity: reduced left‑ventricular ejection fraction. - Severe neutropenia: increased infection risk. - Hemorrhagic events: bleeding tendencies. - Pulmonary hypertension: shortness of breath and fatigue. - Anaphylaxis: rare hypersensitivity reaction requiring immediate medical attention.

Patients and prescribers should consider the following safety measures.

- Baseline monitoring: obtain liver function tests and complete blood count before initiating therapy. - Cardiac assessment: evaluate cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Adherence: encourage consistent dosing to maintain therapeutic plasma levels. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Imatinib may interact with several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering plasma concentrations.

Moderate Interactions (Monitor Closely): - Proton‑pump inhibitors: may modestly affect absorption; monitor therapeutic response. - Anticoagulants (e.g., warfarin): imatinib can alter INR; adjust dose as needed. - Vaccines: live attenuated vaccines should be avoided during treatment. - Diuretics: may exacerbate fluid retention; observe for edema. - Herbal supplements (e.g., St. John's wort): potential CYP3A4 induction; counsel patients on avoidance.